Tools   Select Another Resource Report Type

http://www.edelris.com/

A commercial medicinal chemistry company dedicated to the design and synthesis of natural product-mimetic screening compounds, Hit-to-Lead & Lead Optimization projects and Custom Synthesis. Aiming at the acceleration of the lead discovery and optimization process in pharma and biotech research organizations, EDELRIS uses its validated chemistry and drug discovery expertise to provide novelty to its customers with exclusive or non-exclusive small molecules and with efficient hit-to-lead optimization capabilities. EDELRIS has a wide range of services and based on its experience in various and complementary fields, the team is capable to deliver innovative solutions to synthetic and medicinal chemistry problems faced by clients.

Proper citation: Edelris (RRID:SCR_004112) Copy   

•   Source: SciCrunch Registry

http://www.idbs.com/

Commercial provider of advanced software and solutions that helps R&D teams make discoveries. They provide organizations with the technology they need to securely capture, manage, share and exploit structured and unstructured data. Their technology and domain expertise enables users to link data to data, data to people and people to people to drive innovation, achieve faster time to market and improve margins. Their diverse customer list includes R&D driven international companies in pharmaceuticals, biotechnology, agricultural sciences, chemicals, consumer goods, energy, engineering, food and beverage, and healthcare.

Proper citation: IDBS (RRID:SCR_004077) Copy   

•   Source: SciCrunch Registry

http://www.phenosys.com/

A research- and development-oriented company based in Berlin that engineers and markets technology for animal behavior research offering unique, automated instrumentation. This includes specialized applications of virtual reality and touch screen technology for animal behavior environments and RFID (transponder) operated devices in home cage environments. Their experimental systems are used for behavioral phenotyping, brain research, experimental psychology, and the diagnostic characterization of animal models for translational medicine.

Proper citation: PhenoSys (RRID:SCR_004072) Copy   

•   Source: SciCrunch Registry

http://www.noldus.com/

Commercial organization that develops tools and systems for measurement and analysis of animal and human behavior. They develop instrumented home cage systems, in which rodent behavior and ultrasonic vocalizations can be measured in a non-intrusive manner. Furthermore, they develop computer vision and pattern recognition technology for automated behavior detection. They believe that this approach has significant potential in research on animal models for Autism Spectrum Disorder.

Proper citation: Noldus (RRID:SCR_004074) Copy   

•   Source: SciCrunch Registry

http://www.euadr-project.org/

Consortium that created the capability to detect Adverse Drug Response (ADR) signals by creating the infrastructure for large-scale monitoring of drug safety using electronic health records (EHR). The platform leverages EHR''''s comprising demographics, drug use and clinical data of over 30 million patients from several European countries. Special attention was given to patient groups that are not routinely involved in clinical trials, for ethical or practical reasons (e.g. pregnant women, elderly people, people using many drugs simultaneously, and children). This project also studies and compares a number of different techniques that all aim to detect unexpected or disproportional rates of events. The algorithms that they studied originate not only from the field of (pharmaco)epidemiology, but also from fields such as bio-terrorism, machine learning, and classical signal detection. EU-ADR specific objectives are: To detect events, To relate these events to drugs, To develop hypothesis that explain adverse events, To detect adverse events earlier, and To avoid false positives. The web-based platform is available at https://bioinformatics.ua.pt/euadr/ EU-ADR has contributed to the ability to conduct better drug safety studies based on the re-use of healthcare data. By facilitating the early detection of adverse drug reactions, but also providing key information on populations at risk, potential drug interactions, potential underlying mechanisms and intervening pathways in adverse events, etc., the project will allow for improved and more complete information to be available for drug and healthcare delivery, leading to increased patient safety and its associated cost savings. The EU-ADR system can be considered as a complementary tool to already existing pharamcovigilance systems. Should the system be widespread in the long term, it has the potential to contribute to the development of future electronic health record systems, insofar as the expected benefits of these IT tools are only fully attainable when EHRs develop themselves in consistency, richness and formats that allow them to be subject of such tools. In anticipation, EU-ADR has been designed to be modular and scalable, so that different EHR databases (other than those participating in the Consortium) can be progressively enlisted in the future, adopt the software for data extraction and therefore become susceptible of exploitation by the system, for maximum global effect.

Proper citation: EU-ADR (RRID:SCR_004028) Copy   

•   Source: SciCrunch Registry

http://www.kyushu-u.ac.jp/english/

Japanese national university located in Fukuoka, in the island of Kyushu.

Proper citation: Kyushu University; Fukuoka; Japan (RRID:SCR_004149) Copy   

•   Source: SciCrunch Registry

http://www.cclg.org.uk/index.php

THIS RESORUCE IS NO LONGER IN SERVICE. Documented on April 27,2023. CCLG is an association of healthcare professionals involved in the treatment and care of children and younger teenagers with cancer, and underpins all the activity in pediatric oncology in the British Isles. CCLG is committed to research and development in the treatment of cancer in this age group, the ultimate goal of which is to maximize cure while minimizing the early and late side effects of treatment. Provision of information for patients and families is a core activity. The Children''s Cancer and Leukaemia Group was formed in 2006 as a result of the merger of the UK Children''s Cancer Study Group and the UK Childhood Leukaemia Working Party, both of which had been in existence since the 1970s.

Proper citation: CCLG (RRID:SCR_004137) Copy   

•   Source: SciCrunch Registry

http://www.penta-id.org/

A Level 1 network for pediatric infectious disease in Europe recognized by the European networks of paediatric research at the European Medicines Agency (EnprEMA) whose activities vary from clinical trials, to cohort studies and training. It is currently developing a portfolio of clinical trials in antimicrobials in children, including antibiotics, antivirals and antifungals.

Proper citation: PENTA-ID (RRID:SCR_004092) Copy   

•   Source: SciCrunch Registry

http://www.korea.edu

Korea University is a private research university in Seoul, South Korea. Established in 1905, Korea University is one of the nation oldest and most prominent institutions of higher education. The student body consists of over 20,000 undergraduate students and over 10,000 graduate students. Korea University consists of the Seoul Campus, Sejong Campus and three auxiliary hospitals (Anam Hospital, Guro Hospital, Ansan Hospital).

Proper citation: Korea University; Seoul; South Korea (RRID:SCR_004095) Copy   

•   Source: SciCrunch Registry

https://zenodo.org/

Repository for all research outputs from across all fields of science in any file format as well as both positive and negative results. They assign all publicly available uploads a Digital Object Identifier (DOI) to make the upload easily and uniquely citeable. They further support harvesting of all content via the OAI-PMH protocol. They promote peer-reviewed openly accessible research, and curate uploads. ZENODO allows users to create their own collection and accept or reject all uploads to it. They allow for uploading under a multitude of different licenses and access levels.

Proper citation: ZENODO (RRID:SCR_004129) Copy   

•   Source: SciCrunch Registry

http://www.bccancer.bc.ca/default.htm

A portal that provides a province-wide, population-based cancer control program for the residents of British Columbia and the Yukon. The BC Cancer Agency''s mandate covers the spectrum of cancer care, from prevention and screening, to diagnosis, treatment, and through to rehabilitation. The BC Cancer Agency''s mandate is driven by a three-fold mission: 1. To reduce the incidence of cancer; 2. To reduce the mortality rate of people with cancer; 3. To improve the quality of life of people living with cancer. This mission drives everything we do, including providing screening, diagnosis and care, setting treatment standards, and conducting research into causes of, and cures for, cancer. The BC Cancer Agency operates five regional cancer centers, providing assessment and diagnostic services, chemotherapy, radiation therapy, and supportive care. Each of the BC Cancer Agency''s centers delivers cancer treatment based on provincial standards and guidelines established by the Agency. We work in partnership with communities to provide a network of chemotherapy clinics so patients can receive care closer to home. Research is an essential part of the BC Cancer Agency''s mission to not only find the causes of cancer, but to find better treatments for prolonged life and better quality of life. With direct links between the BC Cancer Agency''s physicians and researchers at our five centers, the Deeley Research Centre (located in Victoria) and the BC Cancer Agency''s Research Centre (located in Vancouver), we can quickly translate new discoveries into clinical applications. The BC Cancer Agency''s Research Centre includes eight specialty laboratories including the Genome Sciences Centre, and the Terry Fox Laboratory. The BC Cancer Foundation raises funds for cancer research and enhancements to care at the BC Cancer Agency.

Proper citation: BC Cancer Agency (RRID:SCR_004201) Copy   

•   Source: SciCrunch Registry

http://www.echelon-inc.com/

An Antibody supplier

Proper citation: Echelon Biosciences (RRID:SCR_004169) Copy   

•   Source: SciCrunch Registry

http://brainarchitecture.org/

Evolving portal that will provide interactive tools and resources to allow researchers, clinicians, and students to discover, analyze, and visualize what is known about the brain's organization, and what the evidence is for that knowledge. This project has a current experimental focus: creating the first brainwide mesoscopic connectivity diagram in the mouse. Related efforts for the human brain currently focus on literature mining and an Online Brain Atlas Reconciliation Tool. The primary goal of the Brain Architecture Project is to assemble available knowledge about the structure of the nervous system, with an ultimate emphasis on the human CNS. Such information is currently scattered in research articles, textbooks, electronic databases and datasets, and even as samples on laboratory shelves. Pooling the knowledge across these heterogeneous materials - even simply getting to know what we know - is a complex challenge that requires an interdisciplinary approach and the contributions and support of the greater community. Their approach can be divided into 4 major thrusts: * Literature Curation and Text Mining * Computational Analysis * Resource Development * Experimental Efforts

Proper citation: Brain Architecture Project (RRID:SCR_004283) Copy   

•   Source: SciCrunch Registry

http://www.uniprot.org/keywords/

UniProtKB entries are tagged with keywords that can be used to retrieve particular subsets of entries. There are 10 categories of keywords: Biological process Cellular component Coding sequence diversity Developmental stage Disease Domain Ligand Molecular function Post-translation modification Technical term You may browse by hierarchy, search in Keywords, or list all keywords. By default, searching the keywords will look for matches in both name and definition.

Proper citation: UniProtKB Keywords (RRID:SCR_004313) Copy   

•   Source: SciCrunch Registry

http://www.mbfbioscience.com/

A provider for commercial products for analyzing neuronal morphology, stereology, etc.

Proper citation: MicroBrightfield, Inc. (RRID:SCR_004314) Copy   

•   Source: SciCrunch Registry

http://www.upenn.edu/

University of Pennsylvania is private Ivy League research university located in University City neighborhood of Philadelphia, Pennsylvania. Established in 1740, UPenn has 4 undergraduate schools and 12 graduate schools.

Proper citation: University of Pennsylvania; Philadelphia; USA (RRID:SCR_004275) Copy   

•   Source: SciCrunch Registry

http://taylorlab.ucsf.edu/software_data.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documentedt on January 10, 2023. Software that implements babel routines for identifying unusual ribosome protected fragment counts given mRNA counts, THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Babel (RRID:SCR_004307) Copy   

•   Source: SciCrunch Registry

http://code.google.com/p/perm/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on February 28,2023. Software package to perform highly efficient genome scale alignments for hundreds of millions of short reads produced by the ABI SOLiD and Illumina sequencing platforms. It capable of providing full sensitivity for alignments within 4 mismatches for 50bp SOLID reads and 9 mismatches for 100bp Illumina reads.Efficient mapping of short sequencing reads with periodic full sensitive spaced seeds.

Proper citation: PerM (RRID:SCR_004223) Copy   

•   Source: SciCrunch Registry

http://www.egappreviews.org/

Initiative to develop a systematic, evidence-based process for evaluating genetic tests and other applications of genomic technology that are rapidly moving from research to use in clinical practice. A key objective of this process is to provide objective, timely, and credible information that is clearly linked to the scientific evidence on specific applications of genetic and genomic tests. The primary focus of EGAPP activities is an independent, nonfederal expert panel, the EGAPP Working Group. Other components of the EGAPP initiative include a federal interagency, the CDC staff and consultants, and an EGAPP initiative evaluation team.

Proper citation: EGAPP (RRID:SCR_004189) Copy   

•   Source: SciCrunch Registry

http://SchistoDB.net

SchistoDB is a genomic database for the parasitic organism Schistosoma mansoni, one of the major causative agents of schistosomiasis worldwide. It currently incorporates sequences and annotation for S. mansoni in a single user-friendly database. Several genomic scale analyses are available as well as ESTs, oligonucleotides, metabolic pathways and drugs. Make your data available: If you''d like to have your updates and/or datasets integrated in SchistoDB, drop us an email.

Proper citation: Schistosoma mansoni Database (RRID:SCR_004341) Copy   

•   Source: SciCrunch Registry